Tricyclic derivative inhibitor, and preparation method and use therefor
Highly selective PRMT5-MTA inhibitors address the toxicity issues of non-selective PRMT5 inhibitors by targeting MTAP-deficient cells, improving therapeutic outcomes in tumour treatment.
AU2024390818A1Pending Publication Date: 2026-07-16SHANGHAI HANSOH BIOMEDICAL CO LTD +1
View PDF 0 Cites 0 Cited by
Patent Information
- Application Number
- AU2024390818
- Authority / Receiving Office
- AU · AU
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-09-27
- Filing Date
- 2024-12-02
- Publication Date
- 2026-07-16
Abstract
A tricyclic derivative inhibitor, and a preparation method and use therefor. In particular, the present invention relates to a tricyclic derivative compound, a preparation method therefor and a pharmaceutical composition containing the compound, and a use thereof in treating cancer.
Need to check novelty before this filing date? Find Prior Art